Study details
Enrolling now
TB006 Trial for Autism Spectrum Disorder
Rossignol Medical Center
NCT IDNCT06500637ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
45
Study length
about 2 years
Ages
18–35
Locations
2 sites in AZ, CA
About this study
Researchers are testing a new medication, TB006, to treat autism spectrum disorder. The trial will last 727 days and involve adults. Participants will be randomly assigned to receive either TB006 or a placebo.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take TB006
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Psychiatry / Mental Health